The total number of hospitalizations with acute kidney injury increased from 953,926 in 2000 to 1,823,054 in 2006 and then further to 3,959,560 in 2014 in the USA. Diabetes was associated with comorbidity in 38%, 37%, and 40% of all hospitalizations in these years, respectively
Comprehensive insight on patient segmentation based on stages (Stage – I, II, III), Coexisting conditions (CAD, CHF, CLD, Cancers, Diabetes, Hypertension, HIV, etc.), and Acute hospital-related factors (Sepsis, Cardiac catheterization, and Cardiac surgery) has been provided into the epidemiology (Incidence and Prevalence) section of the AKI and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China
In terms of pharmacologic therapies, Several drug candidates are in Phase II and II/ III stages of development by various companies. Key assets among these are, BB3 from Angion Biomedi-ca, QPI1002 from Quark Pharmaceutical, recAP from AM-Pharma, THR-184 from Thrasos Therapeutics, EA230 from Exponential Bio-therapies, Simdax from Orion Pharma, bRESCAP from Alloksys, Plastomitin from Mitotech Pharma. Among these key assets, some of the assets are being designated as orphan drugs and fast track. While there is a lot of competitive activity going on in the pipeline for AKI, companies like Angion Biomedica; BB3 holds both Fast Track and Orphan drug designation, however, AM-Pharma, Thrasos Therapeutics holds Fast Track designation. Apart from the above development Kringle Pharma; HGF (Recombinant Protein), Sentien Biotechnologies; SBI-101, and ATO Bio; Reltecimod are also in the race to build their product portfolio within the AKI space.
About Thelansis:
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Other Reports:-
Activated PI3Kdelta Syndrome (APDS) – Market Insight, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Contact details:-
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact no.: +91(124) 404-1731
Sales office
183-Asylum Street Hartford, CT-06103, USA
USA +1 (267) 244-6955,
clientsupport@thelansis.com
m.berg@thelansis.com
Contact Information:
m.berg@thelansis.com
Tags:
Reportedtimes, PR-Wirein, iCN Internal Distribution, Research Newswire, English